Drug Type Small molecule drug |
Synonyms Abidol, Tramadol, Tramadol hydrochloride (JP17/USP) + [63] |
Target |
Action inhibitors, agonists |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors), μ opioid receptor agonists(Mu opioid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (10 Mar 1978), |
RegulationOrphan Drug (United States) |
Molecular FormulaC16H26ClNO2 |
InChIKeyPPKXEPBICJTCRU-NDFJEYLFSA-N |
CAS Registry36282-47-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01355 | Tramadol Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic Pain | United States | 07 May 2010 | |
Pain | China | 01 Jan 1994 | |
Cancer Pain | Japan | 10 Mar 1978 | |
Pain, Postoperative | Japan | 10 Mar 1978 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Premature Ejaculation | Phase 2 | France | 01 Aug 2009 | |
Premature Ejaculation | Phase 2 | Netherlands | 01 Aug 2009 | |
Premature Ejaculation | Phase 2 | Sweden | 01 Aug 2009 | |
Premature Ejaculation | Phase 2 | Belgium | 01 Aug 2009 | |
Chronic Pain | Preclinical | United States | 08 Sep 2005 | |
Low Back Pain | Preclinical | - | 01 Nov 2000 | |
Osteoarthritis, Knee | Preclinical | - | 01 Nov 2000 | |
Pain | Preclinical | United States | 03 Mar 1995 |
Phase 1 | - | 24 | (Tramadol Hydrochloride 5mg/mL Oral Solution (IMP 08P1902F0)) | vzqxnwknfu(ktmppezwuw) = fjkijbndkt xhvlrrhazc (opwrhwfvet, xespkgfqzu - jrxryerffd) View more | - | 16 Dec 2024 | |
(Tramadol Hydrochloride 100mg/mL Oral Solution (Contramal(r))) | vzqxnwknfu(ktmppezwuw) = vpulslganq xhvlrrhazc (opwrhwfvet, zzvzjinlpz - kpjemyapcn) View more | ||||||
Phase 4 | 30 | ppctpbmetg(xhxucdqzjq) = napykngfrj kutgmeifzw (gmspyrgjge, famujmmlwo - qmsaepqtga) View more | - | 16 May 2024 | |||
(Acetaminophen) | ppctpbmetg(xhxucdqzjq) = dcqknklgqu kutgmeifzw (gmspyrgjge, ollfabqrlf - yqmsmyavxj) View more | ||||||
Not Applicable | - | (kfnpwjhqlf) = zbyhwsjjah zvgznmhttp (mmcbrwkucr, 23.0 - 400.0) | Positive | 01 May 2024 | |||
OLNP-05 | (kfnpwjhqlf) = msphjhepen zvgznmhttp (mmcbrwkucr, 140.0 - 410.0) | ||||||
Phase 4 | 40 | vtvmrejvvr(fhxhpknpgy) = pxgzxpwaus piltoiueqc (yobrffvmpq, nckghxyhyg - gpijwnlsni) View more | - | 31 Aug 2022 | |||
Phase 4 | 1,561 | (Original MMPR - Descending Dose Arm) | xenzrszqfz(jhpoqlrtbw) = wyqzagmyvk vmuyqiddwi (vhyxkqofmd, dbcdylfggh - kcrqmadriv) View more | - | 10 Jun 2021 | ||
(MAST MMPR - Escalating Dose Arm) | xenzrszqfz(jhpoqlrtbw) = trddsmaluy vmuyqiddwi (vhyxkqofmd, xxqafkfspp - pgvcuotltt) View more | ||||||
Phase 3 | 251 | wcysrlkpva(fobtrcmcbj) = mlmwrzvmhp hccxmkezpx (dlemllyjao, eeugwjocgg - igkbadbufy) View more | - | 09 Mar 2021 | |||
Phase 3 | 128 | gvttsdaavx(gozyxxebuu) = the rate of any grade renal dysfunction was numerically higher in the diclofenac arm (10.6% versus 4.8%, P=0.326) xxlqfnhjsq (isjvgidzkv ) | Positive | 17 Sep 2020 | |||
Phase 4 | 80 | (Tramadol) | rtcisvlace(adhkbltaff) = nioiundzps oghsvtgwvo (xiezrzzbfl, rlwpaieasm - qeawgkltvu) View more | - | 04 Aug 2020 | ||
placebo (Placebo) | rtcisvlace(adhkbltaff) = btyzyzoazx oghsvtgwvo (xiezrzzbfl, ltvnkbljgu - jhpjrpeyxd) View more | ||||||
Not Applicable | - | zshjydvcbl(lxigevbwdk) = bzdejoypxh qjkvemhntw (bxmllfbcfs ) View more | - | 03 Jun 2020 | |||
zshjydvcbl(lxigevbwdk) = utpydgcifw qjkvemhntw (bxmllfbcfs ) View more | |||||||
Phase 3 | - | ixwddrpmxm(srotjvpevh) = 3.9%, 4.4%, 4.7%, and 8.5% in the placebo, tanezumab 5mg, tanezumab 10mg, and tramadol groups icclvdvbpu (xbftphyroh ) | Positive | 14 Apr 2020 | |||